Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 5 years ago

Possible Interaction: 3-Nitrotyrosine and Rosiglitazone

Research Papers that Mention the Interaction

“ Rosiglitazone significantly reduced plasma nitrotyrosine , high-sensitivity C-reactive protein, and von Willebrand antigen (P < .03 for all) and significantly increased plasma adiponectin (P < .05).”
Metabolism: clinical and experimental  •  2009  |  View Paper
“Immunohistochemical reactions against ICAM-1 and nitrotyrosine showed that rosiglitazone decreased the intensity of inflammatory reactions in the groups of treated animals.”
Medical science monitor : international medical journal of experimental and clinical research  •  2009  |  View Paper
“Administration of rosiglitazone and 15d-PGJ2 also markedly reduced the nitrotyrosine , PARP and inducible nitric oxide synthase formation.”
European Respiratory Journal  •  2005  |  View Paper
“Immunohistochemical analysis revealed that rosiglitazone inhibited the formation of nitrotyrosine , a marker for peroxynitrite reactivity, in the lung tissue.”
Critical care medicine  •  2005  |  View Paper
“Furthermore, rosiglitazone reduced: (1) the increase in the staining (immunohistochemistry) for nitrotyrosine and poly (ADP-ribose) polymerase (PARP), (2) the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), intercellular adhesion molecules-1 (ICAM-1) and P-selectin in the lungs of carrageenan-treated rats.”
European journal of pharmacology  •  2004  |  View Paper
“Treatment with rosiglitazone enhanced PPAR&ggr; expression, improved endothelium-dependent vasodilatation, preserved P-VASP, suppressed gp91phox and iNOS expression, reduced superoxide and total NOx production, and inhibited nitrotyrosine formation.”
Circulation  •  2003  |  View Paper
“Administration of rosiglitazone and 15d-PGJ2 also markedly reduced the nitrotyrosine formation and the upregulation of ICAM-1 during reperfusion.”
British journal of pharmacology  •  2003  |  View Paper